{"text": "TITLE:\n      Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects \u2265 1 Years of Age\nSUMMARY:\n      Demonstrate non-inferiority of the immune response between new versus the currently\n      recommended intradermal regimens of rabies vaccine when administered with or without rabies\n      immunoglobulins in healthy subjects \u2265 1 years of age.\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n          1. Healthy males and females \u2265 1 years of age\n          2. Individuals/ individual's parents or legal guardians who have given written consent\n          3. Individuals in good health\n          4. Individuals who can comply with study procedures\n        Exclusion Criteria:\n          1. Behavioral or cognitive impairment or psychiatric disease.\n          2. Unable to comprehend and to follow all required study procedures for the whole period\n             of the study.\n          3. History of illness or with an ongoing illness that may pose additional risk to the\n             individual if he/she participates in the study.\n          4. Individuals \u2265 1 to \u2264 17 years of age, who have or ever had a malignancy.\n          5. Individuals \u2265 18 years of age, who have or who within the last 5 years, have had a\n             malignancy (excluding nonmelanotic skin cancer) or lymphoproliferative disorder.\n          6. Known or suspected impairment of the immune system (including but not limited to HIV,\n             autoimmune disorders, immunosuppressive therapy as applicable).\n          7. Female of childbearing potential who has not used any of the \"acceptable\n             contraceptive methods\" for at least 2 months prior to study entry.\n          8. Female of childbearing potential, refusal to use an \"acceptable birth control method\"\n             through day 50.\n          9. Female of childbearing potential, with a positive pregnancy test prior to enrollment.\n         10. Received blood, blood products and/or plasma derivatives or any parenteral\n             immunoglobulin preparation in the previous 12 weeks.\n         11. Allergic to any of the vaccine components.\n         12. Allergic to any of the human rabies immunoglobulin components.\n         13. Contraindication or precaution against rabies vaccination.\n         14. Contraindication or precaution against man rabies immunoglobulin administration.\n         15. Planning to receive anti-malaria medications (e.g. Mefloquine) 14 days prior to day 1\n             vaccination through day 50.\n         16. Participating in any clinical trial with another investigational product 30 days\n             prior to first study visit or intent to participate in another clinical study at any\n             time during the conduct of this study.\n         17. Received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for\n             live vaccines) prior to enrollment in this study or who are planning to receive any\n             vaccine within 28 days from the study vaccines.\n         18. Body temperature \u2265 38.0\u00b0C (\u2265 100.4\u00b0F) within 3 days of intended study vaccination.\n         19. Received rabies vaccines or rabies immunoglobulin or have been exposed to rabies.\n         20. Part of the study personnel or immediate family members of study personnel conducting\n             this study.\n         21. Current or history of drug or alcohol abuse within the past 2 years.\n", "cuis": "C0034496 C0021027 C0202081 C0481219 C0202083 C2825347 C0020843 C0577612 C0202086 C0020852 C0202087 C3536873 C0202084 C0085297 C0034494 C1114365 C0040808 C2945654 C1552616 C1706244 C1704632 C1706817 C2911692 C1578513 C0034496 C2945654 C0040808 C0034494 C0021027 C0020852 C0202081 C0020843 C0481219 C0085297 C0239984 C0850992 C0553533 C2748351 C0243161 C0013893 C0243161 C3244317 C3539129 C0021228 C0025664 C0184661 C0947630 C0243161 C0338656 C1270972 C3554639 C2986890 C2707008 C0012634 C0018609 C1548428 C3526598 C0025664 C0184661 C3245501 C3245502 C1619636 C1299582 C0025344 C0947630 C0947630 C0262926 C2004062 C0221423 C0424228 C0947630 C0021228 C0006826 C1306459 C3842363 C3843406 C3842265 C0024314 C1955861 C0272217 C0027022 C1292778 C0007114 C0006826 C1306459 C3842363 C0684336 C3845945 C2598156 C3834249 C4049609 C4049610 C4050368 C0021079 C0455630 C0004364 C0847092 C0851816 C0021053 C2222792 C0700589 C1869110 C0947630 C1561542 C0700589 C2004464 C2078738 C2222792 C1561538 C0240802 C0151865 C0430066 C2584394 C0430059 C3888021 C1516879 C2222792 C0456388 C0030547 C2359959 C0032105 C0005768 C0229664 C0606968 C0021027 C0020843 C0020852 C0202081 C0481219 C0085297 C0553533 C2748351 C0202083 C2825347 C0577612 C0202086 C0202087 C3536873 C0202084 C0201467 C0850992 C0071888 C0040165 C0041014 C0528271 C0608117 C0036679 C0042210 C3467963 C0301503 C1442930 C3467963 C0042205 C0728859 C0419723 C0419724 C0419725 C1301624 C1547316 C3714732 C0301503 C1442930 C1301624 C1547316 C3714732 C1533734 C0376495 C0199808 C0199810 C0725057 C1536282 C0001563 C0036589 C0150270 C3469597 C0013227 C2094204 C0802604 C2598133 C2081612 C0033045 C0025153 C0032074 C0024530 C0206255 C1744563 C1561538 C0042196 C2713304 C0058773 C0419749 C1561538 C3245491 C1552578 C0013230 C0220825 C1261322 C1096775 C3842337 C0947630 C1512346 C3272565 C0947630 C0042212 C0042210 C0042211 C3888021 C1516879 C0032074 C0947630 C0042210 C0947630 C0487995 C0886414 C1369887 C1370085 C0042196 C2713304 C0058773 C0419749 C1551357 C0947630 C0301503 C1442930 C0034496 C0332157 C0034494 C1697779 C0947630 C0034770 C0947630 C0085762 C0262926 C2004062 C0013227 C1254351 C3843646 C3843647 ", "concepts": "Rabies Vaccine, Immunoglobulin, NOS, Immunoglobulins NOS, Immunoglobulin, Immunoglobulin A, Immunoglobulin A, immunoglobulin D, Immunoglobulin D, Immunoglobulin E, immunoglobulin G, Immunoglobulin G, Immunoglobulin G, Immunoglobulin M, Immunoglobulins, IV, Rabies, Age, Regimen, regimens summary, summary Response, Response, Response, new rabies vaccine, regimens, regimen, rabies immunoglobulin, g immunoglobulins, Immunoglobulin, immunoglobulin D, Immunoglobulin, IV immunoglobulin, high immunoglobulins, immunoglobulins test, low immunoglobulin, CSF immunoglobulin criteria, Eligibility Criteria given, Legal guardian, individuality procedures, Procedures, study Criteria cognitive impairment, Mild cognitive impairment, Severe cognitive impairment, Behavioral, Behavior, disease, h disease, Psychiatric, Psychiatric procedures, Procedures, required, required, Required, Unable, period, study study History, History, illness, Stillness study, individuality malignancy, Malignancy, No malignancy, 13-17 years of age 1-5 years lymphoproliferative disease, lymphoproliferative disorder, T-gamma, Atypical lymphoproliferative disorder, Myeloproliferative disorder, myeloproliferative disorder, skin cancer, malignancy, Malignancy, No malignancy impairment, No impairment, Impairments, Unlimited, Unlimited, Unlimited, Unlimited Immunosuppressive therapy, NOS, H/O: immunosuppressive therapy, autoimmune disorders, Blood autoimmune disorders, Autoimmune disorders NEC, immune disorder OT potential contraceptive methods, Contraceptive methods male, study, month birth control methods, birth control method, IUD as birth control method, OT potential day positive pregnancy test, false positive pregnancy tests, Sensitive pregnancy test, Date of positive pregnancy test, Urine pregnancy test positive, enrollment, Enrollment, OT potential blood products, parenteral, Parenteral, plasma, blood, blood, derivative V immunoglobulins, Immunoglobulin D, Immunoglobulin G, Immunoglobulins, Immunoglobulin, IV immunoglobulin, low immunoglobulin, CSF immunoglobulin, Immunoglobulin A, Immunoglobulin A, Immunoglobulin D, Immunoglobulin E, Immunoglobulin G, Immunoglobulin G, Immunoglobulin M, immunoglobulin type, immunoglobulin test, h preparation, T4 preparation, T3 preparation, preparation LB, preparation 31, Separation vaccine, Allergican rabies immunoglobulin, Anti-Rabies immunoglobulin, Allergican Rabies vaccination NOS, rabies vaccinations, First rabies vaccination, 2nd rabies vaccination, Third rabies vaccination, contraindication, Contraindication, Contraindication rabies immunoglobulin, Anti-Rabies immunoglobulin, contraindication, Contraindication, Contraindication, administration, Readministration, Dpt administration, Mmr administration, administration sets, Maladministrations, oral administration, self administration, Drug administration, drug administration medications, medications:, Medications, Medications, medication:, Premedications, Mefloquine, Planning, malarias, malaria, malari, day vaccination, Revaccinations, DT vaccination, vaccination dt, day investigational, investigation, investigational drug, Investigation, Investigation, clinical trial, 0 days study, visit, Clinical study inactivated vaccines, vaccines live vaccines, enrollment, Enrollment, planning, study vaccine, study Body temperature, Body temperature, Body temperature panel, Body temperature panel, vaccination, Revaccinations, DT vaccination, vaccination dt, intended, study rabies immunoglobulin, Anti-Rabies immunoglobulin, rabies vaccines, exposed, rabies immediate, study, remembers study alcohol abuse, history, history, drug, drug, 1-2 years, > 2 years "}
